RESEÑA DE LA CRISIS DE GOBERNABILIDAD DE LA CIUDAD

1. Pui, C.H. & Evans, W.E. Drug therapy - Treatment of acute lymphoblastic leukemia. New

England Journal of Medicine 354, 166-178 (2006).

2. Pui, C.H., Carroll, W.L., Meshinchi, S. & Arceci, R.J. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 29, 551-565 (2011).

3. Nguyen, K., et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children’s Oncology Group study. Leukemia 22, 2142-2150 (2008).

4. Robison, L.L. Late effects of acute lymphoblastic leukemia therapy in patients diagnosed at 0-20 years of age. Hematology Am Soc Hematol Educ Program 2011, 238-242 (2011).

5. Oeffinger, K.C., Nathan, P.C. & Kremer, L.C. Challenges after curative treatment for childhood cancer and long-term follow up of survivors. Hematol Oncol Clin North Am 24, 129-149 (2010).

6. Goldman, J.M. & Melo, J.V. Chronic myeloid leukemia--advances in biology and new approaches to treatment. N Engl J Med 349, 1451-1464 (2003).

7. Bhojwani, D. & Pui, C.H. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol

14, e205-217 (2013).

8. Romana, S.P., et al. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood 85, 3662-3670 (1995).

9. Shurtleff, S.A., et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis.

Leukemia 9, 1985-1989 (1995).

10. Golub, T.R., et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 92, 4917-4921 (1995).

11. Zelent, A., Greaves, M. & Enver, T. Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia. Oncogene 23, 4275-4283 (2004). 12. McLean, T.W., et al. TEL/AML-1 dimerizes and is associated with a favorable outcome in

childhood acute lymphoblastic leukemia. Blood 88, 4252-4258 (1996).

13. Loh, M.L., et al. Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood 107, 4508-4513 (2006).

14. Seeger, K., et al. TEL-AML1 fusion in relapsed childhood acute lymphoblastic leukemia. Blood

94, 374-376 (1999).

15. Ford, A.M., et al. Origins of “late” relapse in childhood acute lymphoblastic leukemia with TEL-AML1 fusion genes. Blood 98, 558-564 (2001).

16. Kuster, L., et al. ETV6/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling. Blood 117, 2658-2667 (2011). 17. van Delft, F.W., et al. Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia.

Blood 117, 6247-6254 (2011).

18. Stams, W.A., et al. Incidence of additional genetic changes in the TEL and AML1 genes in DCOG and COALL-treated t(12;21)-positive pediatric ALL, and their relation with drug sensitivity and clinical outcome. Leukemia 20, 410-416 (2006).

19. Tsuzuki, S., Seto, M., Greaves, M. & Enver, T. Modeling first-hit functions of the t(12;21) TEL- AML1 translocation in mice. Proc Natl Acad Sci U S A 101, 8443-8448 (2004).

20. Hong, D., et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 319, 336-339 (2008).

21. Schindler, J.W., et al. TEL-AML1 corrupts hematopoietic stem cells to persist in the bone marrow and initiate leukemia. Cell Stem Cell 5, 43-53 (2009).

22. van der Weyden, L., et al. Modeling the evolution of ETV6-RUNX1-induced B-cell precursor acute lymphoblastic leukemia in mice. Blood 118, 1041-1051 (2011).

23. Castor, A., et al. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med 11, 630-637 (2005).

24. Anderson, K., et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469, 356-361 (2011).

25. Mullighan, C.G., et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446, 758-764 (2007).

26. Diakos, C., et al. RNAi-mediated silencing of TEL/AML1 reveals a heat-shock protein- and survivin-dependent mechanism for survival. Blood 109, 2607-2610 (2007).

27. Fuka, G., et al. Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts. Leukemia 26, 927-933 (2012).

28. Mangolini, M., et al. STAT3 mediates oncogenic addiction to TEL-AML1 in t(12;21) acute lymphoblastic leukemia. Blood 122, 542-549 (2013).

29. Torrano, V., Procter, J., Cardus, P., Greaves, M. & Ford, A.M. ETV6-RUNX1 promotes survival of early B lineage progenitor cells via a dysregulated erythropoietin receptor. Blood

118, 4910-4918 (2011).

30. Diakos, C., et al. TEL-AML1 regulation of survivin and apoptosis via miRNA-494 and miRNA-320a. Blood 116, 4885-4893 (2010).

31. Roudaia, L., et al. CBFbeta is critical for AML1-ETO and TEL-AML1 activity. Blood 113, 3070- 3079 (2009).

32. Gefen, N., et al. Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53.

Leukemia 24, 89-96 (2010).

33. Palmi, C., et al. Cytoskeletal Regulatory Gene Expression and Migratory Properties of B Cell Progenitors are Affected by the ETV6-RUNX1 Rearrangement. Mol Cancer Res (2014). 34. Ford, A.M., et al. The TEL-AML1 leukemia fusion gene dysregulates the TGF-beta pathway in

early B lineage progenitor cells. J Clin Invest 119, 826-836 (2009).

35. Inthal, A., et al. Role of the erythropoietin receptor in ETV6/RUNX1-positive acute lymphoblastic leukemia. Clin Cancer Res 14, 7196-7204 (2008).

36. Yeoh, E.J., et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1, 133-143 (2002). 37. Den Boer, M.L., et al. A subtype of childhood acute lymphoblastic leukaemia with poor

treatment outcome: a genome-wide classification study. Lancet Oncol 10, 125-134 (2009). 38. Gandemer, V., et al. Five distinct biological processes and 14 differentially expressed genes

characterize TEL/AML1-positive leukemia. BMC Genomics 8, 385 (2007).

39. Andersson, A., et al. Molecular signatures in childhood acute leukemia and their correlations to expression patterns in normal hematopoietic subpopulations. Proc Natl Acad Sci U S A 102, 19069-19074 (2005).

40. Fine, B.M., et al. Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia. Blood 103, 1043-1049 (2004).

41. Fuka, G., Kauer, M., Kofler, R., Haas, O.A. & Panzer-Grumayer, R. The leukemia-specific fusion gene ETV6/RUNX1 perturbs distinct key biological functions primarily by gene repression. PLoS One 6, e26348 (2011).

3

42. van der Veer, A., et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 122, 2622-2629 (2013).

43. Min, I.M., et al. The transcription factor EGR1 controls both the proliferation and localization of hematopoietic stem cells. Cell Stem Cell 2, 380-391 (2008).

44. Laurenti, E., et al. The transcriptional architecture of early human hematopoiesis identifies multilevel control of lymphoid commitment. Nat Immunol 14, 756-763 (2013).

45. Vicente, C., Conchillo, A., Garcia-Sanchez, M.A. & Odero, M.D. The role of the GATA2 transcription factor in normal and malignant hematopoiesis. Crit Rev Oncol Hematol 82, 1-17 (2012).

46. Gupta, P., et al. PU.1: An ETS family transcription factor that regulates leukemogenesis besides normal hematopoiesis. Stem Cells Dev 15, 609-617 (2006).

47. Crispino, J.D. GATA1 in normal and malignant hematopoiesis. Semin Cell Dev Biol 16, 137-147 (2005).

48. Jaber, N., et al. Class III PI3K Vps34 plays an essential role in autophagy and in heart and liver function. Proc Natl Acad Sci U S A 109, 2003-2008 (2012).

49. Kihara, A., Noda, T., Ishihara, N. & Ohsumi, Y. Two distinct Vps34 phosphatidylinositol 3-kinase complexes function in autophagy and carboxypeptidase Y sorting in Saccharomyces cerevisiae. J Cell Biol 152, 519-530 (2001).

50. Miller, S., et al. Shaping development of autophagy inhibitors with the structure of the lipid kinase Vps34. Science 327, 1638-1642 (2010).

51. Funderburk, S.F., Wang, Q.J. & Yue, Z. The Beclin 1-VPS34 complex--at the crossroads of autophagy and beyond. Trends Cell Biol 20, 355-362 (2010).

52. Munster, T., et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum 46, 1460-1469 (2002).

53. Rangwala, R., et al. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy 10, 1369-1379 (2014). 54. Bernardin, F., et al. TEL-AML1, expressed from t(12;21) in human acute lymphocytic

leukemia, induces acute leukemia in mice. Cancer Res 62, 3904-3908 (2002).

55. Fan, D., et al. Stem cell programs are retained in human leukemic lymphoblasts. Oncogene (2014).

56. Levine, B. & Klionsky, D.J. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 6, 463-477 (2004).

57. Mizushima, N. & Komatsu, M. Autophagy: renovation of cells and tissues. Cell 147, 728-741 (2011).

58. Guo, J.Y., Xia, B. & White, E. Autophagy-mediated tumor promotion. Cell 155, 1216-1219 (2013).

59. Mathew, R., Karantza-Wadsworth, V. & White, E. Role of autophagy in cancer. Nat Rev Cancer

7, 961-967 (2007).

60. Levine, B. & Kroemer, G. Autophagy in the pathogenesis of disease. Cell 132, 27-42 (2008). 61. White, E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer

12, 401-410 (2012).

62. Gump, J.M., et al. Autophagy variation within a cell population determines cell fate through selective degradation of Fap-1. Nat Cell Biol 16, 47-54 (2014).

63. Avramis, V.I. Asparaginases: biochemical pharmacology and modes of drug resistance.

64. Willems, L., et al. Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood 122, 3521-3532 (2013).

65. Pieters, R., et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer 117, 238-249 (2011).

66. Fujisaki, J., et al. In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche. Nature 474, 216-219 (2011).

67. Arai, F., et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 118, 149-161 (2004).

68. McMillin, D.W., Negri, J.M. & Mitsiades, C.S. The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov 12, 217-228 (2013).

69. Amaravadi, R.K., et al. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 17, 654-666 (2011).

70. Rosenfeld, M.R., et al. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 10, 1359-1368 (2014).

71. Rangwala, R., et al. Combined MTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy 10, 1391-1402 (2014).

72. Vogl, D.T., et al. Combined autophagy and proteasome inhibition: A phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.

Autophagy 10, 1380-1390 (2014).

73. Maes, H., et al. Tumor Vessel Normalization by Chloroquine Independent of Autophagy.

Cancer Cell 26, 190-206 (2014).

74. Eng, C.H., et al. Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy. Proc Natl Acad Sci U S A 113, 182-187 (2016).

75. McAfee, Q., et al. Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proc Natl Acad Sci U S A 109, 8253-8258 (2012).

76. Bago, R., et al. Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase. Biochem J 463, 413-427 (2014).

77. Ronan, B., et al. A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy. Nat Chem Biol 10, 1013-1019 (2014).

78. Dowdle, W.E., et al. Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo. Nat Cell Biol 16, 1069-1079 (2014).

3